Outcomes Analysis of Delayed Antibiotic Treatment for Hospital-Acquired Staphylococcus aureus Bacteremia

Lodise, Thomas P.; McKinnon, Peggy S.; Swiderski, Linda; Rybak, Michael J.
June 2003
Clinical Infectious Diseases;6/1/2003, Vol. 36 Issue 11, p1418
Academic Journal
The objective of this study was to determine the effect of delayed therapy on morbidity and mortality associated with nosocomial Staphylococcus aureus bacteremia. The study included all episodes of S. aureus bacteremia that developed >2 days after hospital admission during 1999 to 2001. Classification and regression tree analysis (CART) was used to select the mortality breakpoint between early and delayed treatment. During the 25-month study period, 167 patients met the inclusion criteria. The breakpoint between delayed and early treatment derived using CART was 44.75 hours. On multivariate analysis, delayed treatment was found to be an independent predictor of infection-related mortality (odds ratio, 3.8; 95% confidence interval, 1.3-11.0; P = .01) and was associated with a longer hospital stay than was early treatment (20.2 days versus 14.3 days; P = .05). These findings support the notion that delay of therapy has deleterious effects on clinical outcomes, and efforts should be made to ensure that appropriate therapy is initiated promptly.


Related Articles

  • Therapy of Staphylococcus aureus Bacteremia Associated with a Removable Focus on Infection. Iannini, Paul B.; Crossley, Kent // Annals of Internal Medicine;May76, Vol. 84 Issue 5, p558 

    Presents a study which investigated the duration or therapy necessary to eradicate Staphylococcus aureus bacteremia in patients with removable source of infection. Methodology; Results of the study.

  • Is reduced vancomycin susceptibility a factor associated with poor prognosis in MSSA bacteraemia? López-Cortés, L. E.; Velasco, C.; Retamar, P.; del Toro, M. D.; Gálvez-Acebal, J.; de Cueto, M.; García-Luque, I.; Caballero, F. J.; Pascual, A.; Rodríguez-Baño, J. // Journal of Antimicrobial Chemotherapy (JAC);Sep2015, Vol. 70 Issue 9, p2652 

    Objectives: The known data about the influence of vancomycin MIC on Staphylococcus aureus bacteraemia are contradictory. Our objective was to study the possible impact of vancomycin MIC ≥1.5 mg/L on short- and medium-term mortality. Methods: A prospective cohort study was carried out from...

  • Staphylococcus aureus Small Colony Variants: Difficult to Diagnose and Difficult to Treat. Vaudaux, Pierre; Kelley, William L.; Lew, Daniel P. // Clinical Infectious Diseases;10/15/2006, Vol. 43 Issue 8, p968 

    The article comments on the article by Sendi and colleagues regarding the difficulties inherent in the diagnosis and treatment of Staphylococcus aureus small colony variants. The authors acknowledge that a lack of awareness initially contributed to ineffective surgical revisions and...

  • Antimicrobials: Cholesterol-biosynthesis inhibitor stops infection. Crunkhorn, Sarah // Nature Reviews Drug Discovery;Apr2008, Vol. 7 Issue 4, p291 

    The article presents a study which demonstrates that compounds designed to lower cholesterol levels in humans could treat methicillin-resistant Staphylococcus aureus (MRSA). In the study, the researchers examined the structure of an essential enzyme involved in the first crucial step of...

  • Emergence, Mechanism, and Clinical Implications of Reduced Glycopeptide Susceptibility in Staphylococcus aureus. Geisel, R.; Schmitz, F.J.; Fluit, A.C.; Labischinski, H. // European Journal of Clinical Microbiology & Infectious Diseases;Oct2001, Vol. 20 Issue 10, p685 

    In order to understand the mechanism(s) of the resistance/reduced susceptibility of Staphylococcus aureus to glycopeptide antibiotics, the current data on the modes of action of glycopeptides were reviewed. In addition, the different test systems for detecting vancomycin resistance and the...

  • Community-acquired MRSA's surprising targets. Creech, C. Buddy; Saravolatz, Louis D.; Schaffner, William // Patient Care;Jul2005, Vol. 39 Issue 7, p30 

    Presents information on community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA). Risk factors for nosocomial MRSA; Drugs to which CA-MRSA is susceptible; Description of skin infections caused by CA-MRSA; Treatment options for CA-MRSA.

  • Elimination of Coincident Staphylococcus aureus Nasal and Hand Carriage with Intranasal Application of Mupirocin Calcium Ointment. Reagan, David R.; Doebbeling, Bradley N.; Pfaller, Michael A.; Sheetz, Carol T.; Houston, Alison K.; Hollis, Richard J.; Wenzel, Richard P. // Annals of Internal Medicine;1/15/91, Vol. 114 Issue 2, p101 

    Presents information on a study which determined the safety and efficacy of mupirocin calcium ointment in the elimination of Staphylococcus aureaus nasal and hand carriage in healthy persons. Methods; Results; Discussion.

  • Effect of Mastitis on Pharmacokinetics of Levofloxacin Following Single Dose Intravenous Administration in Goats. Ram, Mahendra; Singh, Vishakha; Roy, Birendra Kumar; Prasad, Raju; Singh, Kaushal Kumar // Journal of Bioanalysis & Biomedicine;2011, Vol. 3 Issue 5, p81 

    Disposition kinetics of levofloxacin was investigated after single dose intravenous administration at the dose of 10 mg/kg in six healthy and six mastitic Black Bengal lactating goats. Mastitis was induced in goats by coagulase positive Staphylococcus aureus. The maximum milk concentration was...

  • Daptomycin for Bacteremia and Endocarditis Due to S. aureus.  // Clinical Infectious Diseases;1/15/2007, Vol. 44 Issue 2, pvi 

    The article focuses on the clinical trial comparing the efficacy of daptomycin with standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. In a trial, S. aureus patients were treated with neither daptomycin nor vancomycin. At the initiation of therapy, patients not...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics